SLC5A2 and chronic kidney disease: In particular, knowing that fibrosis is often triggered not only by mechanical effects but also by inflammatory processes, Oxa represents, for example, an option for a potentially even more efficient therapy compared to the SGLT-2 inhibitors currently newly approved for the slowing of progression in chronic renal failure (Wheeler et al., 2021; The et al., 2023).